📊 RTGN Key Takeaways
Is RetinalGenix Technologies Inc. (RTGN) a Good Investment?
RetinalGenix is in acute financial distress with negative stockholders equity of -2.2M against only 7K in assets, indicating technical insolvency. The company has no identifiable revenue, is losing 1.8M annually, and is burning cash at 430K per quarter with only $92 remaining—a trajectory pointing toward imminent collapse or restructuring.
Why Buy RetinalGenix Technologies Inc. Stock? RTGN Key Strengths
- No strengths identified
RTGN Stock Risks: RetinalGenix Technologies Inc. Investment Risks
- Negative stockholders equity of -2.2M indicates technical insolvency and going concern risks
- Nearly zero liquidity (7K assets vs 2.2M liabilities; only $92 cash on hand) with no capacity to fund operations
- Severe cash burn of 430K per quarter with no revenue generation; runway exhausted within weeks
- Extreme ROA of -25788.7% demonstrates catastrophic operational failure and value destruction
- No evidence of profitability, revenue generation, or operational viability in latest filings
- Zero insider buying activity in past 90 days suggests no confidence from company leadership
Key Metrics to Watch
- Quarterly cash balance and burn rate—any filing showing cash depletion below operational needs triggers bankruptcy risk
- Revenue emergence or business activity—any positive revenue would be material sign of turnaround; currently shows none
- Debt restructuring or capital raise announcements—essential for survival but would heavily dilute existing equity
RetinalGenix Technologies Inc. (RTGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RTGN Profit Margin, ROE & Profitability Analysis
RTGN vs Healthcare Sector: How RetinalGenix Technologies Inc. Compares
How RetinalGenix Technologies Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RetinalGenix Technologies Inc. Stock Overvalued? RTGN Valuation Analysis 2026
Based on fundamental analysis, RetinalGenix Technologies Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RetinalGenix Technologies Inc. Balance Sheet: RTGN Debt, Cash & Liquidity
RTGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: RetinalGenix Technologies Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.12 indicates the company is currently unprofitable.
RTGN Revenue Growth, EPS Growth & YoY Performance
RetinalGenix Technologies Inc. Dividends, Buybacks & Capital Allocation
RTGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RetinalGenix Technologies Inc. (CIK: 0001836295)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RTGN
What is the AI rating for RTGN?
RetinalGenix Technologies Inc. (RTGN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RTGN's key strengths?
Claude: .
What are the risks of investing in RTGN?
Claude: Negative stockholders equity of -2.2M indicates technical insolvency and going concern risks. Nearly zero liquidity (7K assets vs 2.2M liabilities; only $92 cash on hand) with no capacity to fund operations.
What is RTGN's revenue and growth?
RetinalGenix Technologies Inc. reported revenue of N/A.
Does RTGN pay dividends?
RetinalGenix Technologies Inc. does not currently pay dividends.
Where can I find RTGN SEC filings?
Official SEC filings for RetinalGenix Technologies Inc. (CIK: 0001836295) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RTGN's EPS?
RetinalGenix Technologies Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RTGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RetinalGenix Technologies Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RTGN stock overvalued or undervalued?
Valuation metrics for RTGN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RTGN stock in 2026?
Our dual AI analysis gives RetinalGenix Technologies Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RTGN's free cash flow?
RetinalGenix Technologies Inc.'s operating cash flow is $-430.1K, with capital expenditures of N/A.
How does RTGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).